Document is current
Any future updates will be listed below
-
Authors
Rofail, Diana
Somersan-Karakaya, Selin
Mylonakis, Eleftherios
Choi, Julia Y.
Przydzial, Krystian
Marquis, Sarah
Zhao, Yuming
Hussein, Mohamed
Norton, Thomas D.
Podolanczuk, Anna J.
Geba, Gregory P.
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals (N/A)
Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development Authority (HHSO100201700020C)
- License Information
-
More Information
Article History
Received: 25 September 2023
Accepted: 20 May 2024
First Online: 9 August 2024
Declarations
:
: All study documents including the protocol, demographic and health information form, interview guide, screener, and informed consent form were submitted to the WIRB (Western Institutional Review Board) and Copernicus Group Institutional Review Board (WCG-IRB) and approved [IRB tracking #20214272]. All patients were ≥18 years and written informed consent was obtained electronically prior to participants taking part in the study; all participants were provided a copy of the fully signed consent form.
: Not applicable.
: D.R. is a Regeneron Pharmaceuticals, Inc. employee/stockholder, and former Roche employee and current stockholder. S.S.-K., Y.Z., M.H., T.D.N., and G.P.G. are employees/stockholders at Regeneron Pharmaceuticals, Inc. EM reports payments to his institution received from SciClone Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Pfizer, Chemic Labs/KODA Therapeutics, Cidara, and Leidos Biomedical Research Inc./NCI; and reports advisory board: Basilea; and grants from NIH/NIAID, NIH/NIGMS, and BARDA. J.Y.C., and K.P. are employees of Modus Outcomes and consulted for Regeneron Pharmaceuticals, Inc. A.J.P. reported receiving personal fees from Regeneron Pharmaceuticals, Inc. during the conduct of the study, personal fees from Imvaria, Boehringer Ingelheim, EBSCO/Dynamed, and Roche outside the submitted work.
